ETTX

Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer

Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

ETTX Stock Price: Over 40% Increase Pre-Market Details

Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.

Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference